A compound ketoconazole preparation for pets and preparation method thereof
By simplified preparation of components such as Chinese aloe vera polypeptide and ketoconazole, the problems of multiple components and complex preparation of compound ketoconazole in the prior art have been solved, and more efficient treatment of pet skin diseases and mite removal effects have been achieved. Reduces costs and improves treatment effectiveness.
Patent Information
- Application Number
- CN202411200076.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The existing compound ketoconazole preparations for pets have many components and are complex in preparation, and the antibacterial and mite removal functions are uneven, resulting in poor treatment effects.
Using Chinese aloe vera polypeptide (GTFQDMKRIVAY sequence) combined with ketoconazole and metronidazole, it is prepared by cellulase and trypsin enzymatic decomposition, simplifying components and isolating polypeptides of different molecular weights, and preparing it into a compound ketoconazole preparation, suitable for the treatment of pets Skin diseases and removal of mites.
It achieves a more efficient mite-killing effect, reduces the cost of raw materials, simplifies the preparation process, and improves the effect of treating pet skin diseases, especially showing significant therapeutic effects on microsporidium canis infection.
Smart Images

Figure CN118697851B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pet biomedicine, and in particular to a compound ketoconazole preparation for pets and a preparation method thereof. Background Art
[0002] As people's lives become more abundant, more and more people are keeping pets. Although pets are cute, they have too much hair, which makes it easy for them to hide pathogens such as mites, bacteria and fungi, leading to fungal skin diseases, which affects the quality of life and appearance of sick animals. The most common pathogens in clinical fungal skin diseases are dermatophytes and Malassezia, both of which are zoonotic pathogens. Fungi are widely distributed in the environment and are opportunistic pathogens, which means they can only be infected when there is a problem with the body. If it is a simple fungal infection, breeders usually use ketoconazole, etc., but for anaerobic infections, breeders usually use metronidazole, etc. for treatment.
[0003] For example, the prior art CN115671052A discloses a compound ketoconazole spray for pets, which comprises the following components: ketoconazole, metronidazole, menthol, laurocapram, polyethylene glycol 400, and 50% concentration of ethanol.
[0004] Prior art CN114376942A discloses a pet skin external lotion, comprising the following raw materials in parts by weight: a cleaning detergent and an active ingredient, wherein the cleaning detergent comprises decyl glucoside, lauryl glucoside, sodium laureth sulfate, cocamide, sodium lauroyl glutamate, methyl glucose dioleate, ethylene glycol distearate, and disodium edetate; and the active ingredient comprises chlorhexidine acetate, chlorhexidine digluconate, ketoconazole, fluconazole, itraconazole, clotrimazole, benzoyl peroxide, phytosphingosine, vitamin B6, niacinamide, tocopherol, bisabolol, and hydroxyphenylpropionamide benzoic acid.
[0005] Prior art CN111135176B discloses a pet external bactericidal, anti-inflammatory and disinfectant spray and a preparation method thereof. The spray is composed of the following components by mass percentage: ketoconazole, polyhexamethylene guanidine / biguanide hydrochloride, dimenoic acid, glycerol and alcohol.
[0006] Prior art CN107648308A discloses an external ointment for treating pet skin diseases and a preparation method thereof, which uses ketoconazole, metronidazole, peppermint oil, Solidago scabra extract, and auxiliary materials as raw material components.
[0007] Prior art CN107625765B discloses a preparation method and application of a compound ketoconazole ointment. In the preparation method, ketoconazole, metronidazole, menthol, anhydrous sodium sulfite, surfactant, hydrochloric acid and other active substances and adjuvants are used as main raw materials, and the preparation method process is adjusted and optimized, so that the prepared compound ketoconazole ointment has stable properties and good bactericidal properties, can effectively treat pet skin diseases, and can also be further used in the preparation of therapeutic drugs containing ketoconazole or metronidazole.
[0008] Prior art CN117797238A discloses a preparation process and application of a stable compound miconazole nitrate solution, which includes chlorhexidine gluconate, miconazole nitrate, antimicrobial peptide solution, dimethyl sulfoxide, propylene glycol, and ethanol solution, wherein the antimicrobial peptide solution is one of a surfactant solution and a composite surfactant solution. The compound miconazole nitrate solution has the advantages of good drug resistance, stability, and moisture retention, and has a better effect on the treatment of skin diseases in dogs and cats. The three-drug formula can continue to act throughout the onset of pet skin diseases, and can effectively combat fungal and bacterial infections of dog and cat skin, shortening the treatment cycle.
[0009] Prior art CN117137839A discloses a pet shampoo with antibacterial and anti-mite functions, comprising: an antibacterial agent, sodium polyoxyethylene fatty alcohol ether sulfate, an amino acid surfactant, an alkyl glycoside, cocamidopropyl betaine, coconut oil diethanolamide, an essence, an anti-mite agent, a traditional Chinese medicine extract, a pH regulator, a thickener, a chelating agent, a conditioner, a preservative, and deionized water.
[0010] However, the above-mentioned prior arts all contain multiple components, the preparation process is complicated, the antibacterial and anti-mite functions are uneven, and the dosage form is single. Therefore, this application will simplify the components and try to obtain a more effective compound ketoconazole preparation for pets and a simpler preparation method. Summary of the invention
[0011] In order to solve the above problems, the present invention first provides a compound ketoconazole preparation for pets, wherein the compound ketoconazole preparation comprises aloe polypeptide;
[0012] In certain embodiments, the polypeptide sequence is GTFQDMKRIVAY.
[0013] In certain embodiments, the Aloe vera is Aloe vera.
[0014] In certain embodiments, the polypeptide has a molecular weight of less than 2 KDa.
[0015] In certain embodiments, the compound ketoconazole preparation further comprises ketoconazole and metronidazole;
[0016] In certain embodiments, the compound ketoconazole preparation further comprises allantoin, eucalyptus oil, dp300, salicylic acid, camphor, and borneol.
[0017] In certain embodiments, the compound ketoconazole formulation further comprises ethanol.
[0018] In certain embodiments, the aloe polypeptide is prepared by enzymatically hydrolyzing aloe with cellulase and trypsin.
[0019] In certain embodiments, the ratios of cellulase and trypsin are 0.4% and 0.2%, respectively.
[0020] The present invention also provides a method for preparing the above-mentioned compound ketoconazole preparation for pets, the method comprising the following steps:
[0021] (1) Take 200 g of fresh Aloe vera (aloe vera var. chinesis) leaves, wash them with 500 ml of PBS buffer, peel them and crush them with a tissue grinder, soak them in 2 volumes of PBS buffer, stir for 2 h, and filter them with gauze to obtain the residue and supernatant 1;
[0022] (2) Transfer the filter residue in step (1) to a large beaker, add 500 mL of deionized water to the large beaker, and then place the beaker in a water bath, stir at 55°C for 2 h to obtain a colloidal mixed solution; after cooling to 45°C, add cellulase (0.4%) and trypsin (0.2%), stir and hydrolyze for 3 h; centrifuge at 3000 g for 15 min to obtain supernatant 2;
[0023] (3) The supernatant 2 is filtered and concentrated using a nanofiltration membrane alone or in combination to separate and purify polypeptide solutions of different molecular weights. The supernatant 2 is desalted using a dialysis bag (100 Da), concentrated by rotary evaporation, and freeze-dried to obtain freeze-dried powder, which is stored in a -20°C refrigerator for later use.
[0024] In certain embodiments, the nanofiltration membrane has a membrane molecular cut-off of 3 KDa and 2 KDa.
[0025] Finally, the present invention provides an application of the compound ketoconazole preparation for pets, which is used to prepare a product for treating pet skin diseases or removing mites;
[0026] In certain embodiments, the pet skin disease is caused by a single infection or a mixed infection of Microsporum canis, Trichophyton mentagrophytes and Gypsum gypseum fungi.
[0027] In certain embodiments, the product is in the form of one or more of a liniment, a spray, a paint, a soak, a drop, or a pour-on, a cream, and a gel.
[0028] Compared with the prior art, the present invention has at least the following beneficial effects:
[0029] The present invention directly uses Chinese aloe enzymatic hydrolysis to obtain Chinese aloe polypeptide for the first time. Compared with the prior art using a combination of multiple western medicines or a combination of multiple traditional Chinese medicines, the components are more streamlined, and the acquisition cost of aloe is lower than that of other traditional Chinese medicines or western medicines, thus opening up a new source of raw materials, while also saving costs and being more conducive to market promotion.
[0030] The present invention separates Chinese aloe polypeptides of different molecular weights, points out the direction for further refined utilization of aloe, and identifies that the polypeptide sequence GTFQDMKRIVAY has better mite and sterilization effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Peptide identification diagram. DETAILED DESCRIPTION
[0032] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0033] Example 1 Extraction of Aloe Vera polypeptide:
[0034] Take 200 g of fresh Aloe vera (aloe vera var. chinesis) leaves, wash them with 500 ml of PBS buffer, peel them and crush them with a tissue grinder, soak them in 2 times the volume of PBS buffer, stir for 2 hours, and filter them with gauze to obtain the residue and supernatant 1;
[0035] (2) Transfer the filter residue in step (1) to a large beaker, add 500 mL of deionized water to the large beaker, and then place the beaker in a water bath, stir at 55°C for 2 h to obtain a colloidal mixed solution; after cooling to 45°C, add cellulase (0.4%) and trypsin (0.2%), stir and hydrolyze for 3 h; centrifuge at 3000 g for 15 min to obtain supernatant 2;
[0036] (3) The supernatant 2 was filtered and concentrated using a nanofiltration membrane with a membrane molecular cutoff of 3KDa and 2KDa, either alone or in combination, to separate and purify five kinds of polypeptide solutions with molecular weights, namely A (>3KDa), B (<3KDa), C (>2KDa), D (<2KDa), and E (2KDa-3KDa). The polypeptide solutions with the above five kinds of molecular weights and the supernatant 2 were collected and desalted using a dialysis bag (100Da), concentrated by rotary evaporation, and freeze-dried to obtain six kinds of freeze-dried powders (A, B, C, D, E and supernatant 2), which were stored in a -20℃ refrigerator for later use.
[0037] Example 2 Mite removal effect experiment:
[0038] The six kinds of freeze-dried powders prepared in Example 1 were all prepared at 50 mg / mL. With reference to T / CIAA017-2022 "Test Method and Evaluation of Anti-mite and Mite Removal Performance of Household Cleaning Products", the sample of Example 1 of the present invention was exposed to the water for 48 hours, and the number of dead mites was recorded and observed to examine its mite removal performance. The test results are shown in Table 1 below:
[0039] Table 1 Mite killing effect of each component in Example 1
[0040]
[0041] From the results in Table 1, it can be seen that D (<2KDa) freeze-dried powder has a significant mite-killing effect compared with other groups. The mass spectrum test results of D show that its amino acid sequence is GTFQDMKRIVAY, see Figure 1 Therefore, in subsequent experiments, D (<2KDa) lyophilized powder was mainly used for experiments, and other components were used as controls.
[0042] Example 3 Preparation of compound ketoconazole preparation for pets:
[0043] This embodiment provides a method for preparing a compound ketoconazole preparation for pets, which specifically comprises the following steps:
[0044] (1) Weigh lyophilized powder, ketoconazole, metronidazole, propylene glycol, polysorbate 80 and β-cyclodextrin according to Table 2;
[0045] (2) Mix propylene glycol and polysorbate 80 in a water bath at 65-80°C and homogenize for 10 minutes to obtain an additive solution;
[0046] (3) Add ketoconazole and metronidazole to the auxiliary agent solution obtained in step (2) and fully dissolve them. Maintain the solution temperature at 60° C. and mix. Stir evenly to obtain the main material.
[0047] (4) The lyophilized powder obtained in step (1) and the main material obtained in step (3) are mixed at 60° C., β-cyclodextrin is slowly added and stirred, an appropriate amount of purified water is added, stirred, and cooled to room temperature to obtain a compound ketoconazole preparation.
[0048] Table 2 Components of compound ketoconazole preparations in each experimental group (mass percentage)
[0049]
[0050] Example 4 Composition effectiveness test:
[0051] Test drugs: Composition 1 to Composition 14 prepared in Example 3;
[0052] Experimental animals: 320 cats and dogs aged 10 months, selected from a breeding base in Suzhou City, Jiangsu Province. Clinical manifestations include psoriasis, hair loss, dandruff, etc., and microscopic examination showed that they were infected with Microsporum canis.
[0053] Experimental procedures: 320 naturally infected cats and dogs (half cats and half dogs, half males and half females, cats in each group had similar weights, dogs in each group had similar weights) were divided into 16 groups, 20 in each group. The experimental group was topically applied with the composition prepared in Example 3, the composition was applied to the affected part once a day for 7 consecutive days; the control group was topically applied with ZEFNART SOLUTION (purchased from Japan) 2%, the drug was applied to the affected part once a day for 7 consecutive days; the blank control group was topically applied to the affected part once a day for 7 consecutive days.
[0054] Criteria for judging efficacy:
[0055] Curative medication: The isolation and conversion rate of pathogenic bacteria on the skin is ≥80%, and at the same time, the skin itching symptoms disappear and the dandruff disappears significantly.
[0056] Effective medication: The isolation and conversion rate of pathogenic bacteria on the skin is ≥60%, and the symptoms of skin itching are alleviated and dandruff is reduced.
[0057] Ineffective medication: The rate of negative conversion of pathogenic bacteria in the skin was less than 60%, and there were still obvious itching symptoms, and no reduction in dandruff. The test data were statistically analyzed, and the results are shown in Table 3.
[0058] Table 3 The therapeutic effects of different compositions on pet pathogens
[0059]
[0060] Table 3 shows that the composition 1 of the present invention has the best therapeutic effect on Microsporum canis in cats and dogs.
[0061] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A Chinese Aloe polypeptide; the polypeptide sequence is GTFQDMKRIVAY.
2. A compound ketoconazole preparation for pets, characterized in that: The compound ketoconazole preparation comprises Aloe vera polypeptide; the polypeptide sequence is GTFQDMKRIVAY.
3. The compound ketoconazole preparation according to claim 2, characterized in that: The compound ketoconazole preparation also contains ketoconazole and metronidazole.
4. An application of the polypeptide according to claim 1 or the compound ketoconazole preparation for pets according to any one of claims 2-3, characterized in that: The application is to prepare products for treating pet skin diseases and removing mites; the pet skin diseases are caused by infection with Microsporum canis.
5. The use according to claim 4, characterized in that: The dosage form of the product is one or more of liniment, spray, paint, soaking agent, drops, pour-on, cream and gel.
